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Background and the purpose of the study: Helicobacter pylori is recognized as the main cause of gastritis and
gastroduodenal ulcers and classified as class 1 carcinogen pathogen. Different 1,3,4-thiadiazole derivatives bearing
5-nitroaryl moiety have been shown considerable anti- H. pylori activity. In attempt to find new and potent
derivatives of described scaffold, a new series of 1-(substituted benzyl)-4-(5-(5-nitroaryl-2-yl)-1,3,4-thiadiazol-2-yl)
piperazine derivatives were synthesized and evaluated against three metronidazole-resistant isolates of H. pylori
using paper disk diffusion bioassay test.
Methods: The title compounds were prepared through the reaction of 1-(5-(5-nitroaryl-2-yl)-1,3,4-thiadiazol-2-yl)
piperazine 5a-b and substituted benzyl chloride in DMF. The inhibitory activity of the new derivatives 6a-q against
three metronidazole-resistant isolates of H. pylori was evaluated by the disc diffusion method and compared with
the commercially available standard drug metronidazole.
Results and discussion: The results of SAR study indicated that the potency and anti-H. pylori activity profile of
synthesized derivatives is mainly attributed to the substituted nitroaryl moiety at the C-5 position of 1,3,4-thiadiazole
ring. Most of 1,3,4-thiadiazole derivatives bearing 5-nitrofuran moiety at C-5 position of central thiadiazole ring,
demonstrated more promising anti-H. pylori than the 5-nitrothiophen counterpart.
Conclusion: The most potent nitrofuran derivative containing 3-methoxybenzyl piperazine pendant at the C-2 position
of 1,3,4-thiadiazole ring (compound 6i), demonstrated strong anti-H. pylori potential at studied concentrations 100-25
μg/disk (IZD > 20 mm) against all studied metronidazole- resistant isolates of H. pylori.
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Helicobacter pylori, an spiral-shaped Gram-negative bac-
terium, has been considered as the leading cause of gas-
tritis and gastroduodenal ulcer in developing countries.
H. pylori is also classified as the class 1 carcinogen
pathogen because of its epidemiological relationship to
gastric adenocarcinoma and gastric mucosa-associated
lymphoid tissue lymphoma [1-3]. Therefore; treatment* Correspondence: ashafiee@ams.ac.ir
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the Creative Commons Attribution License (ht
distribution, and reproduction in any mediumof Helicobacter pylori requires targeted therapeutic
strategy.
Different studies show that eradication of H. pylori in-
fection resulted to ulcer healing and reduced prevalence
of gastric cancer [4]. However, treatment of this infec-
tion is complicated and successful eradication of this or-
ganism is continuously requiring a combination regime
using a minimum of two different antibiotics plus proton
pump inhibitor (PPI) agent [3,5,6].
Although several combination therapy regimes using
various anti-bacterial agents through different duration
of therapy are proposed for eradication of H. pylori in-
fection, emergence of resistance strains is a growing glo-
bal concern. Clinical evaluation of current therapeuticMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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infection relapses and side effects of common drugs [7,8].
These factors have been the rationale for the development
of new anti- Helicobacter pylori drugs and search for novel
therapeutic molecules that offer better protection and de-
creased relapse towards resistant strains.
Nitrofuran and nitrothiophene heterocyclic derivatives
have been extensively studied in therapy against different
microbial infections [9-11]. Moreover, the antimicrobial
and anti-Helicobacter property of 1,3,4-thiadiazole moiety
is well established and attachment of this antimicrobial
scaffold with nitro-hetrocyclic moieties would accommo-
date the bioresponses and antimicrobial activity depending
on the type of substituted group and position of attach-
ment [12-14]. In our previous works, we have investigated
the anti-Helicobacter potential of different 5-(5-nitroaryl)-
1,3,4-thiadiazole scaffold bearing different C-2 attached
pendants. Among different nitroheterocycles, 5-nitrofuran,
5-nitrothiophen and 5-nitroimidazole moieties are pref-
erable for substitution at C-5 position of 1,3,4-thiadiazole
ring. These nitroheteroaromatic moieties mimic the
nitroaromatic part of nitroheterocyclic drugs such as
metronidazole and furazolidon (Figure 1) [11,14-17].Figure 1 Chemical structure of current nitroheterocyclic drugs (Metro
infection and designed 5-(nitroaryl)-1,3,4-thiadiazoles bearing piperazIn continuation of our research program to find a
novel antibacterial agent [18], we have previously dem-
onstrated the considerable antibacterial activity of 5-
nitroimidazole-based 1,3,4-thiadiazoles bearing cyclic
amine functionality such as pyrrolidine and piperazine
derivatives at the C-2 position of thiadiazole ring
against resistant strains of Helicobacter pylori [15]. In
order to find the structural requirement of cyclic amine
derivatives of 5-(nitroaryl)-1,3,4-thiadiazole as anti-H. pyl-
ori agents, herein, we describe the synthesis and anti-
Helicobacter evaluation of a new series of 5-(nitrothienyl)
and 5-(nitrofuryl)-1,3,4-thiadiazoles containing different




A Kofler hot stage apparatus was used for the measurement
of reported melting. The IR spectra were recorded on a
Nicollet FT-IR Magna 550 spectrometer. The 1H NMR
spectra were recorded on a Varian FT-400 MHz or Bruker
FT-500 MHz spectrometer and chemical shifts (δ) are
reported in ppm relative to internal tetramethylsilane. Thenidazole and Furazolidone) used in the treatment of H.pylori
ine derivatives 6a-q.
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(Ion trap) VL instrument. at 70 eV. Fross- Heraeus CHN-O
rapid analyzer was used for elemental analysis of syn-
thesized compounds and the results are within ± 0.4%
of the theoretical values. Analytical thin-layar chroma-
tography (TLC) on Merck silicagel 60 F254 plates using
various mobile phases of different polarities was performed
in order to confirm the purity of final products.
General method for the synthesis of 1-substitutedbenzyl-4-
(5-(5-nitroaryl-2-yl)-1,3,4-thiadiazol-2-yl)piperazine 6a-q
To a mixture of 1-(5-(5-nitroaryl-2-yl)-1,3,4-thiadiazol-2-
yl)piperazine 5a-b (1.0 mmol) and different benzyl chlor-
ide derivatives (1.0 mmol) in DMF (15 mL), NaHCO3
(0.21 mmol) was added and the resulted mixture was
stirred at room temperature overnight. After completion
of the reaction, water was added, and the resulted precipi-




Yield 40%; m.p. 219-221°C; IR(KBr): 1343, 1527 cm-1
(NO2);
1H-NMR(CDCl3) δ: 2.48-2.64 (m, 4H, pipera-
zine), 3.48-3.63 (m, 2H, CH2), 3.48-3.63 (m, 4H, pipera-
zine), 7.16 (bs, 1H, thiophene), 7.45 (bs, 1H, phenyl),
7.52-7.60 (m, 2H, phenyl), 7.80-7.92 (m, 2H, phenyl-
thiophene); MS: m/z (%) 432 (M+, 1), 415 (21), 241 (15),
191 (81), 172 (15), 136 (100), 120 (33), 91 (34), 69 (93),
42 (25). Anal. Calcd. For C17H16N6O4S2: C, 47.21; H,
3.73; N, 19.43; Found: C, 47.03; H, 3.51; N, 19.67.
1-(3-nitrobenzyl)-4-(5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-
2-yl)piperazine (6b)
Yield 33%; m.p. 205-206°C; IR(KBr): 1344, 1528 cm-1
(NO2);
1H-NMR(CDCl3) δ: 2.26-2.69 (m, 4H, pipera-
zine), 3.60-3.72 (m, 4H, piperazine and 2H, CH2), 7.16
(bs, 1H, thiophene), 7.58 (t, 1H, phenyl, J = 7.5Hz), 7.68
(bs, 1H, phenyl), 7.86 (bs, 1H, thiophene), 8.15 (bs, 1H,
phenyl), 8.24 (s, 1H, phenyl); MS: m/z (%) 432 (M+, 2),
241 (14), 191 (88), 172 (14), 155 (16), 136 (100), 111
(16), 90 (60), 73 (18), 56 (47). Anal. Calcd. For
C17H16N6O4S2: C, 47.21; H, 3.73; N, 19.43; Found: C,
47.54; H, 3.61; N, 19.83.
1-(4-nitrobenzyl)-4-(5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-
2-yl)piperazine (6c)
Yield 60%; m.p. 232-234°C; IR(KBr): 1340, 1509 cm-1
(NO2);
1H-NMR(CDCl3) δ: 2.35-2.50 (m, 4H, pipera-
zine), 3.40-3.60 (m, 4H, piperazine and 2H, CH2), 7.02
(s, 1H, thiophene), 7.37 (d, 2H, phenyl, J = 7.6Hz), 7.70
(s, 1H, thiophene), 8.02 (d, 2H, phenyl, J = 7.6 Hz); MS:
m/z (%)432 (M+, 16), 415 (16), 395 (46), 368 (11), 313
(11), 296 (14), 241 (32), 191 (100), 172 (33), 155 (12),136 (77), 106 (31), 78 (37), 56 (30). Anal. Calcd. For
C17H16N6O4S2 C, 47.21; H, 3.73; N, 19.43; Found: C,
47.56; H, 3.99; N, 19.07.
1-(2,6-difluorobenzyl)-4-(5-(5-nitrothiophen-2-yl)-1,3,4-
thiadiazol-2-yl)piperazine (6d)
Yield 31%; m.p. 198-199°C; IR(KBr): 1343, 1503 cm-1
(NO2);
1H-NMR(CDCl3) δ: 2.64-2.76 (m, 4H, piperazine),
3.60-3.71 (m, 4H, piperazine), 3.79 (s, 2H, CH2), 6.92
(t, 3H, phenyl, J= 7.6Hz), 7.14 (d, 1H, thiophene, J= 3.6Hz ),
7.85 (d, 1H, thiophene, J= 3.6Hz); MS: m/z (%) 423 (M+, 2),
182 (100), 166 (30), 127 (100), 111 (15), 83 (21), 57 (31), 41
(23). Anal. Calcd. For C17H15F2N5O2S2: C, 48.22; H, 3.57; N,
16.54; Found: C, 48.49; H, 3.34; N, 16.16.
1-(2,4,5-trifluorobenzyl)-4-(5-(5-nitrothiophen-2-yl)-1,3,4-
thiadiazol-2-yl)piperazine (6e)
Yield 33%; m.p. 213-215°C; IR(KBr): 1342, 1513 cm-1
(NO2);
1H-NMR(CDCl3) δ: 2.64 (bs, 4H, piperazine),
3.59 (s, 2H, CH2), 3.65 (bs, 4H, piperazine), 6.90-7.00
(m, 1H, phenyl), 7.12 (bs, 1H, thiophene), 7.20-7.38 (m,
1H, phenyl), 7.87 (bs, 1H, thiophene); MS: m/z (%) 441
(M+, 5), 241 (13), 200 (86), 182 (19), 145 (100), 128 (11),
69 (11), 42 (14). Anal. Calcd. For C17H14F3N5O2S2: C,




Yield 93%; m.p. 210-211°C; IR(KBr): 1344, 1504 cm-1
(NO2);
1H-NMR(CDCl3) δ: 2.65-2.74 (m, 4H, pipera-
zine), 3.60-3.74 (m, 2H, CH2 and 4H, piperazine), 7.13-
7.32 (m, 3H, phenyl-thiophene), 7.50 (s, 1H, phenyl),
7.86 (d, 1H, thiophene, J = 3.6 Hz); MS: m/z (%) 459 (M++4,
0.4), 457 (M++2, 3), 455 (M+, 4), 214 (93), 192 (18), 159
(100), 123 (18). Anal. Calcd. For C17H15Cl2N5O2S2: C,
44.74; H, 3.31; N, 15.35; Found: C, 44.51; H, 3.70; N, 15.67.
1-(3,4-dichlorobenzyl)-4-(5-(5-nitrothiophen-2-yl)-1,3,4-
thiadiazol-2-yl)piperazine (6g)
Yield 36%; m.p. 183-185°C; IR(KBr): 1343, 1508 cm-1 (NO2);
1H-NMR(CDCl3) δ: 2.51-2.63 (m, 4H, piperazine), 3.52 (s,
2H, CH2), 3.60-3.68 (m, 4H, piperazine), 7.13-7.24 (m, 2H,
phenyl-thiophene), 7.40 (dd, 2H, phenyl), 7.85 (s, 1H, thio-
phene); MS: m/z (%) 459 (M++4, 0.5), 457 (M++2, 3),
455 (M+, 5), 241 (18), 214 (81), 159 (100), 124 (16), 89
(12), 56 (19). Anal. Calcd. For C17H15Cl2N5O2S2: C, 44.74;
H, 3.31; N, 15.35; Found: C, 44.46; H, 3.62; N, 15.14.
1-(4-bromobenzyl)-4-(5-(5-nitrothiophen-2-yl)-1,3,4-
thiadiazol-2-yl)piperazine (6h)
Yield 50%; m.p. 207-208°C; IR(KBr): 1343, 1509 cm-1
(NO2);
1H-NMR(CDCl3) δ: 2.53-2.68 (m, 4H, pipera-
zine), 3.52 (s, 2H, CH2), 3.60-3.69 (m, 4H, piperazine),
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phenyl), 7.85 (s, 1H, thiophene); MS: m/z (%) 467 (M++2,
13), 465 (M+, 14), 296 (16), 280 (14), 265 (10), 254 (41), 239
(100). Anal. Calcd. For C17H16BrN5O2S2: C, 43.78; H, 3.46;
N, 15.02; Found: C, 43.94; H, 3.74; N, 14.78.
1-(3-methoxybenzyl)-4-(5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-
2-yl)piperazine (6i)
Yield 54%; m.p. 126-127°C; IR(KBr): 1355, 1536 cm-1
(NO2);
1H-NMR(CDCl3) δ: 2.63 (t, 4H, piperazine, J =
5.1 Hz), 3.57 (s, 2H, CH2), 3.67 (t, 4H, piperazine, J =
5.1Hz), 3.83 (s, 3H, OCH3), 6.84-6.87 (m, 1H, phenyl),
6.92-6.95 (m, 2H, phenyl), 7.17 (d, 1H, furan, J = 3.7 Hz),
7.21-7.23 (m, 1H, phenyl), 7.44 (d, 1H, furan, J = 3.7 Hz);
MS: m/z (%) 401 (M+, 7), 176 (86), 147 (13), 121 (100),
91 (24), 57 (18), 40 (14). Anal. Calcd. For C18H19N5O4S:




Yield 43%; m.p. 197-199°C; IR(KBr): 1353,1529 cm-1
(NO2);
1H-NMR(CDCl3) δ: 2.62 (t, 4H, piperazine, J =
5.1 Hz), 3.62 (t, 4H, piperazine, J = 5.1 Hz), 3.89 (s, 2H,
CH2), 7.17 (d, 1H, furan, J = 3.8 Hz), 7.44 (d, 1H, furan,
J = 3.8 Hz),7.45-7.48 (m, 1H, phenyl), 7.56-7.59 (m, 2H,
phenyl), 7.85 (d, 1H, phenyl, J = 7.8 Hz); MS: m/z (%)
416 (M+, 2), 399 (46), 381 (13), 225 (18), 191 (86), 166
(14), 136 (100), 105 (12), 78 (44), 56 (19). Anal. Calcd.
For C17H16N6O5S:C, 49.03; H, 3.87; N, 20.18; Found: C,
49.28; H, 3.64; N, 20.42.
1-(3-nitrobenzyl)-4-(5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-
yl)piperazine (6k)
Yield 50%; m.p. 144-146°C; IR(KBr): 1353, 1529 cm-1
(NO2);
1H-NMR(CDCl3) δ: 2.66 (t, 4H, piperazine, J =
5.0 Hz), 3.69 (t, 4H, piperazine, J = 5.0 Hz), 3.71 (s, 2H,
CH2), 7.18 (d, 1H, furan, J = 3.9 Hz), 7.44 (d, 1H, furan,
J = 3.9 Hz ), 7.54 (t, 1H, phenyl, J = 7.9 Hz), 7.71 (d, 1H,
phenyl, J = 7.9 Hz), 8.17 (d, 1H, phenyl, J = 7.9 Hz), 8.26
(bs, 1H, phenyl); MS: m/z (%) 416 (M+, 7), 399 (12), 225
(19), 191 (100), 166 (20), 136 (86), 90 (37), 57 (21), 40
(18). Anal. Calcd. For C17H16N6O5S: C, 49.03; H, 3.87;
N, 20.18; Found: C, 48.88; H, 3.56; N, 20.44.
1-(4-nitrobenzyl)-4-(5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-
yl)piperazine (6l)
Yield 50%; m.p. 212-213°C; IR(KBr): 1348, 1505 cm-1
(NO2);
1H-NMR(CDCl3) δ: 2.65 (t, 4H, piperazine, J =
5.1 Hz), 3.69(s, 2H, CH2), 3.70 (t, 4H, piperazine, J =
5.1 Hz), 7.18 (d, 1H, furan, J = 3.9 Hz), 7.44 (d, 1H, furan,
J = 3.9 Hz), 7.56 (d, 2H, phenyl, J = 8.6 Hz), 8.23 (d, 2H,
phenyl, J = 8.6 Hz); MS: m/z (%) 416 (M+, 9), 399 (13),
225 (21), 191 (100), 166 (12), 136 (87), 106 (36), 78 (49),60 (11), 42 (40). Anal. Calcd. For C17H16N6O5S: C,




Yield 50%; m.p. 176-179°C; IR (KBr): 1353, 1540 cm-1
(NO2);
1H-NMR(CDCl3) δ: 2.69 (t, 4H, piperazine, J =
4.6 Hz), 3.67 (t, 4H, piperazine, J = 4.6 Hz), 3.79 (s, 2H,
CH2), 6.93 (t, 2H, phenyl, J = 7.4 Hz), 7.16 (d, 1H, furan,
J = 3.8 Hz), 7.28-7.38 (m, 1H, phenyl), 7.43 (d, 1H, furan,
J = 3.8 Hz); MS: m/z (%) 407 (M+, 5), 182 (85), 149 (11),
127 (100), 69 (11), 42 (11). Anal. Calcd. For
C17H15F2N5O3S:C, 50.12; H, 3.71;N, 17.19; Found: C,
50.35; H, 3.45; N, 17.54.
1-(2,4,5-trifluorobenzyl)-4-(5-(5-nitrofuran-2-yl)-1,3,4-
thiadiazol-2-yl)piperazine (6n)
Yield 41%; m.p. 174-175°C; IR(KBr): 1355, 1517 cm-1
(NO2);
1H-NMR(CDCl3) δ: 2.65 (t, 4H, piperazine, J =
5.2 Hz), 3.60 (s, 2H, CH2), 3.68 (t, 4H, piperazine, J =
5.2 Hz), 6.84-6.86 (m, 1H, phenyl), 7.18 (d, 1H, furan,
J = 3.8 Hz), 7.25-7.26 (m, 1H, phenyl), 7.74 (d, 1H,
furan, J = 3.8 Hz); MS: m/z (%) 425 (M+, 6), 225 (13),
200 (94), 166 (11), 145 (100), 82 (12). Anal. Calcd. For
C17H14F3N5O3S: C, 48.00; H, 3.32; N, 16.46; Found: C,
48.35; H, 3.44; N, 16.18.
1-(2,5-dichlorobenzyl)-4-(5-(5-nitrofuran-2-yl)-1,3,4-
thiadiazol-2-yl)piperazine (6o)
Yield 92%; m.p. 165-167°C; IR(KBr): 1353, 1549 cm-1
(NO2);
1H-NMR(CDCl3) δ: 2.71 (t, 4H, piperazine, J =
4.6 Hz), 3.67 (s, 2H, CH2), 3.68 (t, 4H, piperazine, J =
4.6 Hz), 7.17 (d, 1H, furan, J = 3.6 Hz), 7.22 (dd, 1H,
phenyl, J = 8.5 Hz, J = 2.0 Hz), 7.32 (d, 1H, phenyl, J =
8.5 Hz, J = 2.0 Hz), 7.45 (d, 1H, furan, J = 3.6 Hz), 7.51
(d, 1H, phenyl, J = 2.0 Hz); MS: m/z (%) 443 (M++4, 0.4),
441 (M++2, 3), 439 (M+, 6), 313 (12), 236 (16), 214 (95),
192 (16), 159 (100), 123 (16), 99 (13), 82 (16), 57 (20), 40
(16). Anal. Calcd. For C17H15Cl2N5O3S: C, 46.37; H,
3.43; N, 15.91; Found: C, 46.65; H, 3.67; N, 15.69.
1-(3,4-dichlorobenzyl)-4-(5-(5-nitrofuran-2-yl)-1,3,4-
thiadiazol-2-yl)piperazine (6p)
Yield 62%; m.p. 161-162°C; IR(KBr): 1353, 1503 cm-1
(NO2);
1H-NMR(CDCl3) δ: 2.62 (t, 4H, piperazine, J =
5.0 Hz), 3.53 (s, 2H, CH2), 3.67 (t, 4H, piperazine, J =
5.0 Hz), 7.17 (d, 1H, furan, J = 3.8 Hz), 7.19 (dd, 1H,
phenyl, J = 8.3 Hz, J = 2.0 Hz), 7.41-7.45(m, 2H, phenyl),
7.47 (d, 1H, furan, J = 3.8 Hz); MS: m/z (%) 443 (M++4,
0.5), 441 (M++2, 3), 439 (M+, 5), 273 (12), 238 (11), 214
(93), 159 (100), 123 (16), 100 (7), 82 (13), 56 (15). Anal.
Calcd. For C17H15Cl2N5O3S: C, 46.37; H, 3.43; N, 15.91;
Found: C, 46.68; H, 3.16; N, 16.09.
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yl)piperazine (6q)
Yield 28%; m.p. 192-193°C; IR(KBr): 1353, 1508 cm-1
(NO2);
1H-NMR(CDCl3) δ: 2.61 (t, 4H, piperazine, J =
5.0 Hz), 3.54 (s, 2H, CH2), 3.66 (t, 4H, piperazine, J =
5.0 Hz), 7.17 (d, 1H, furan, J = 3.9 Hz), 7.23 (d, 2H,
phenyl, J = 8.3Hz), 7.44 (d, 1H, furan, J = 3.9 Hz), 8.25 (d,
2H, phenyl, J = 8.3 Hz); MS: m/z (%) 451 (M++2, 1), 449
(M+, 2), 210 (20), 169 (100), 90 (44), 56 (22), 40 (21).
Anal. Calcd. For C17H16BrN5O3S: C, 45.34; H, 3.58; N,
15.55; Found: C, 45.59; H, 3.92; N, 15.27.
Biological activity
Patients and bacterial strains
Different isolates of H. pylori were obtained from 160
dyspeptic patients consisted of 78 men and 82 women
whose mean ages were 48 and 43 years, respectively.
Based on the endoscopic diagnosis, the patients were
classified into three groups: gastritis (124, 77.5%), ulcers
(32, 20%) and cancer.
Antral biopsies demonstrating positive urease tests were
transported to the microbiology lab in semisolid (0.1%
agar) normal saline. The biopsies were cultured using se-
lective medium containing brucella agar (Merck), 7% defi-
brinated sheep blood, vancomycin (5 mg/L), trimethoprim
(5 mg/L), polymyxin B (50 mg/L), and amphotericin B
(4 mg/L). Incubation of cultured isolates was performed at
37°C under microaerobic conditions (CO2 incubator;
Heraeus, Germany). After 3–5 days, all cultures were ex-
amined for observation of pinpoint (1–2 mm) glistening
colonies. Identification of H. pylori isolates was carried
out according to the spiral microscopic appearance, Gram
negative stain and some biochemical examinations such as
urease, oxidase and catalase positive test and negative ac-
tivities of nitrate and H2S.
The protocol of this research was approved by
Pharmaceutical Sciences Research Center ethics com-
mittee (number 90-3-29: 1-1).
Consent
Written informed consent was obtained from the patient
for the publication of this report.
Antimicrobial susceptibility test
Antimicrobial susceptibility test was performed using disk
diffusion method (DDM). Recruited antibiotics included
metronidazole, tetracycline. In the first step of the suscep-
tibility evaluation, one hundred and ten strains were
recruited. As a result of remarkable resistance of different
studied bacterial isolates to recruited antibiotics and in at-
tempt to increase the accuracy of the metronidazole resist-
ant rates, in the second step of our study, an additional
fifty strains of H. Pylori isolates were recruited for suscep-
tibility testing with metronidazole (32, 16, 8, and 4 μg/mL)and with 2, 1, and 0.5 μg/mL of tetracycline. The suscepti-
bility tests were repeated twice for the resistant strains.
Bacterial suspensions were prepared in normal saline with
the turbidity of Mac-Farland standard No.2 (equivalent to
6 × 108cell/mL). 100 μl of each bacterial suspension were
inoculated in the surface of non- selective blood agar
plates and the culture plates were allowed to dry at room
temperature (10 min). Sterile blank disks were deposited
on the surface of inoculated plates. 10 μL of each anti-
biotic dilution was poured into a blank disk. Moreover,
control plates with growth positive bacterial culture were
prepared using the introduction of 10 μl of the antibiotic
solvent into the blank disks.
Plates were incubated at described condition and the
inhibition zone diameters (IZD) were examined after
3–5 days. Susceptible and resistant isolates of H.pylori
demonstrated IZDs ≥20 mm and ≤10 mm for metro-
nidazole, respectively. The antibacterial activities of target
compounds were evaluated against three metronidazole-
resistant isolates of H. pylori. All experiments were
performed in triplicate and the mean of IZDs produced by
test compounds in four concentrations (100, 50, 25 and
12.5 μg/mL) was considered as antibacterial activity.
Anti-Helicobacter pylori activity assay
As mentioned earlier, the growth inhibitory potential of
test compounds was evaluated against three metronida-
zole resistant isolates of H. pylori by the filter paper disk
diffusion method at 37°C, under microqerophilic condi-
tion on selective Brucella agar with 7% defibrinated
horse blood. Four concentrations of titled compounds in
dimethylsulfoxide (DMSO) were used for evaluation of
anti Helicobacter activity assay. Blank standard disks
(6 mm in diameter) were deposited on the surface of test
plates and impregnated with 10 μL of different concen-
trations of target compounds. Test plates were incubated
at 37°C for 3–5 days and the inhibition zone around
each disk (average diameter) was measured. The control
disks were impregnated with 10 μL of DMSO. All anti-
bacterial activity experiments were performed in tripli-
cate and the antibacterial activity was expressed as the




The synthetic pathway for the target compounds 6a-q is
depicted in the Scheme 1. A mixture of 5-nitroaryl-2-
carboxaldehyde diacetate 1a-b with thiosemicarbazide
was refluxed in ethanol to afford thiosemicarbazone 2a-b.
Amino-1,3,4-thiadiazoles 3a-b, were synthesized through
the oxidative cyclization of 2a-b in presence of ammo-
nium ferric sulfate. In the next step, diazotization of 3a-b
in hydrochloric acid and in the presence of copper powder
Scheme 1 Reagents and conditions: (i) thiosemicarbazide, EtOH, HCl, reflux, 1.5 h; (ii) NH4Fe(SO4)2, 12H2O, H2O reflux, 25 h; (iii) NaNO2,
HCl, Cu, °C→ rt, 3 h; (iv) Piperazine hydrate, EtOH, NaHCO3 1 h; (v) DMF, Substituted benzyl chloride, 4 h.
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1,3,4-thiadiazol-2-yl)piperazine 5a-b were prepared through
the reaction of chloro-1,3,4-thiadiazole derivatives 4a-b with
piperazine hydrate in stirred ethanol.
The prepared key intermediates 5a-b were further reacted
with different substituted benzyl chlorides in refluxing
DMF to give the corresponding 1-substituted-benzyl-4-
(5-(5-nitroaryl-2-yl)-1,3,4-thiadiazol-2-yl)piperazine 6a-q.
The structures of compounds 6a-q were determined using
spectroscopic methods including mass spectrometry,1H
NMR, IR, and elemental analysis. The chemical structure
of target compounds are shown in Figure 2.Anti-Helicobacter pylori activity and structure-activity
relationship study
The in vitro anti-Helicobacter activity of synthesized de-
rivatives was determined by paper disk diffusion bioassay
against three metronidazole resistant H. pylori isolates.
The average of inhibition zone diameters (IZD) of com-
pounds against three isolates at four different concentra-
tions (100, 50, 25 and 12.5 μg/ disk) is summarized in
Figure 2. The anti-H. pylori activity of target derivatives
could be simply categorized as follows: strong response,
zones range diameter >20 mm; moderate response,
zone diameter 16–20 mm; weak response, zone diam-
eter 11–15 mm; and little or no response, zone diam-
eter <10 mm [15].
Investigation of the IZD of studied compounds re-
vealed that the target derivatives demonstrated a widespectrum of anti-H. pylori activity varied from little
(IZD <10 mm) to strong (IZD >20 mm) response at
concentration of 100 μg/disk against metronidazole re-
sistant strains. In view of the obtained data, the following
structure-activity relationship might be developed:
Assessment of nitroheterocyclic moiety
Based on the substituted nitroaromatic group, the stud-
ied 1,3,4-thiadiazole derivatives could be classified into
two groups: Nitrothiophen 6a-h and nitrofuran 6i-q de-
rivatives. The results of anti-H. pylori activity indicated
that the inhibitory responses of test compounds is
mainly attributed to the substituted nitroaryl moiety at
the C-5 position of 1,3,4-thiadiazole ring. While all of
nitrothiophene derivatives 6a-h demonstrated weak
(IZD = 11–15 mm) to little (IZD <10 mm) inhibitory re-
sponse at concentration of 100 μg/disk against three
metronidazole resistant isolates, most of nitrofurane de-
rivatives 6i-q showed strong (IZD > 20 mm) to moderate
(IZD = 16–20) growth inhibitory potential at the same
concentration.
It could be concluded that nitrofuran 6i-q derivatives
of 1,3,4-thiadiazole scaffold, are more potent than the
nitrothiophen 6a-h counterpart.
Investigation of substituted group into the benzyl
piperazine pendant
In order to find the structural requirement of substituted
moiety at C-2 position of 1,3,4-thiadiazole scaffold,
Figure 2 Average of inhibition zone diameters of compounds
6a-q at four different concentrations against three
metronidazole resistant H. pylori isolates.
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at the described position. Among the nitrofuran deriva-
tives 6i-q, 3-methoxybenzyl piperazine derivative 6i,
demonstrated strong anti-H. pylori potential at studied
concentrations 100–25 μg/disk (IZD > 20 mm) against
studied isolates. Investigation of the growth inhibitory
potential of the nitrofuran series 6i-q revealed that sub-
stitution of nitro group at the meta position of the ben-
zyl piperazine side chain, resulted in compound with
strong (IZD = 20 mm) to moderate (IZD = 16–20 mm)
growth inhibitory potential at 100 and 50–12.5 μg/disk,
respectively. However, introduction of nitro substitute at
ortho or para position of the benzyl piperazine pendant,
resulted in compound with diminished inhibitory poten-
tial against resistant strains of H. pylori isolates (com-
pounds 6j (IZD = 16 mm, moderate response) and 6l
(IZD = 11 mm, weak response) respectively). Moreover,
substitution of fluorine groups at different positions of
benzyl pieperzine side chain influenced the growth in-
hibitory potential of compounds which is mainly
dependent on the position and number of substituted
fluorine groups; compound 6n containing 2,4,5-triflouro
benzyl piperazine pendant at C-2 position of 5-
nitrofuran-1,3,4-thiadiazole scaffold, produced strong in-
hibitory response at 100 and 50 μg/disk (IZD =23 and
21 mm, respectively); while the anti-H. pylori potential
of 2,5-difluoro benzyl piperazine counterpart was dimin-
ished to weak (IZD = 12 mm) to no response (IZD =
5 mm) at 100 and 50 μg/disk, respectively.
Conclusion
A novel series of 5-(5-nitroaryl)-1,3,4-thiadiazole deriva-
tives containing various benzyl piperazine moiety at C-2
position of 1,3,4-thiadiazole ring were synthesized and
evaluated against three metronidazole-resistant isolates
of H.pylori using paper disk diffusion bioassay test.
Structure-activity relationship study of these derivatives
indicated that 1,3,4-thiadiazole derivatives bearing 5-
nitrofuran moiety at C-5 position of central thiadiazole
ring, demonstrated more promising anti-H. pylori than
the 5-nitrothiophen counterpart. The most potent nitro-
furan derivative had 3-methoxybenzyl piperazine pen-
dant at the C-2 position of 1,3,4-thiadiazole ring. The
results indicated that the anti-H. pylori potential of the
nitrofurane derivatives of 1,3,4-thiadiazole scaffold is
mainly attributed to the type and position of the
substituted group at the benzyl piperazine pendant. Future
studies may be aimed at designing more potent derivatives
of these series in order to investigate the structure-activity
relationship of cyclic amine derivatives of 5-(nitroaryl)-
1,3,4-thiadiazole derivatives as Anti-H. pylori agents.
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